INFOR	MAT	TION DISCLOSU	RE CITATION	Attorney Docket No. <b>056291-5283</b>			Application No. <b>10/578,663</b>				
	(Us	se several sheets if nece	Applicants: HENNEQUIN et al.								
		PTO Form 1449 December 4, 2008	Filing Date: January 17, 2007			Group Art Unit: 1624					
U.S. PATENT DOCUMENTS											
Initial		Document No.	Date	——————————————————————————————————————	lame	Class	Sub-Class	Filing Date			
	1.	US 2003/0186995	October 2, 2003	Ka	th et al.						
	2.	US 2004/0048880	March 11, 2004	Himme	lsbach et al.						
	ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./										
FOREIGN PATENT DOCUMENTS  Names											
	Document No. Date			Co	Country XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX						
	3.	CA 2476008	October 9, 2003			Boehr:	inger I	ngelheim			
	4.	CA 2543649	May 12, 2005		anada			11			
	5.	WO 01/21596	March 29, 2001		VIPO	Astr	azeneca	Ltd.			
000000000000000000000000000000000000000		WO 2004/046101	Juna3,,2004		VIPQ	000000000000000000000000000000000000000	-	000000000000000000000000000000000000000			
	000000000000000000000000000000000000000	WO 2004/000840	January 22, 2004 February 17, 200		<del>/////////////////////////////////////</del>						
000000000000000000000000000000000000000			occoccoccopppagastropoccoccoccoccoccoccoccoccoccoccoccoccoc		<del>/////////////////////////////////////</del>	000000000000000000000000000000000000000		000000000000000000000000000000000000000			
000000000000000000000000000000000000000	10.	WO 2003/097134	October 20. 2005		VII O	>00000000000000000000000000000000000000	•	000000000000000000000000000000000000000			
ΔΙ		ERENCES CONSI				H. /T.N.	1				
	<u>ila                                      </u>	LITERALO OOMOII	DEITED ENOET	AAIITTITT TIIAT	<u>.u mnood</u>	1. / 1.14.	Λ	<u></u>			
		OTHER DO	OCUMENTS (Includ	ling Author, T	itle, Date, Pert	inent Pag	ges, etc.)				
	11.	Ballard et al. "Develor						properties" Poster -			
		Presented at DMDG C			_						
		Ballard et al. "Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine									
		kinase" Bioorg Med Chem Lett. 17(22):6326-6329 (2007).									
		Barlaam et al. "A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(2):674-678 (2008).									
		Barlaam et al. "Indazolylamino/Anilinoquinazolines Bearing a C-5 substitution as erbB2 kinase inhibitors: Structure-									
		activity relationships and identification of a candidate drug" at AACR in 2007.									
	15.	Barlaam et al. "Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 recept									
		tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(6):1799-1803 (2008) .									
000000000000000000000000000000000000000	16				-6		***************************************	se Inhibitors: Structure-			
000000000000000000000000000000000000000	000000000000	Activity Relationships and Identification of a Candidate Drug" Poster number P044, presented at XXth International  Symposium on Medicinal Chemistry (EFMC ISMC 2008) Vicame, Austria, August 31. September 4, 2008.									
000000000000000000000000000000000000000	1.7	<u> </u>									
		Cockerill et al. "Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2" Bioorganic & Medicinal Chemistry Letters 11(11):1401-1405 (2001).									
		Ducray et al. "Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors" Bioorganic & Medicinal Chemistry Letters 18(3):959-962 (2008).									
		Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-									
	20.	Thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13(4):637-640 (2003).									
		Harris et al. "Systematic variation of a key quinazoline core" Presented at the XXII European Colloquium on Heterocyclic Chemistry (XXII ECHC-2006) Bari, Italy, September 2-6, 2006.									
		Hennequin et al. "N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-									
		yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor" J Med Chem. 49(22):6465-6488 (2006)									
		CHOIH. 17(22).0405-04	(2000) *								
Examiner	L	L	Date C	onsidered	04/09/	2009		***			
		/Tamthom Truon	g/		UT/U3/	~VV3					
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in											
conforman	ce and	not considered. Include	e conv of this form w	ith next commu	nication to ann	licant					

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)  PTO Form 1449 December 4, 2008				Attorney Docket N 056291-5283	No.	Application No. 10/578,663				
				Applicants: HENNEQUIN et al.						
				Filing Date: January 1	7, 2007	Group Art Unit: 1624				
			U.S. PA	TENT DOCUMENTS						
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date			
			FOREIGN	PATENT DOCUMENTS						
		Document No.	Date	Country	Class	Sub-Class	Translation			
***************************************	22.	Jani et al. "Discovery and phar	macologic cl				sine kinase inhibitor"			
	23.	Cancer Research 67(20):9887- Klutchko et al. "Tyrosine kinas			ilinoquinazo	olines and 4-an	ilinopyrido[3,4-			
		d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors" J Med Chem. 49(4):1475-14 (2006).								
	24.	Petrov et al. "Optimization and series" Bioorg Med Chem Lett			kinase inhib	ition in the 6-fi	uranylquinazoline			
		ALL REFERENCES	CONSIDE	RED EXCEPT WHERE	E LINED TH	 HROUGH. /	 Г.N./			
		,								
<del></del>										
	<b> </b>									
					,					
Examiner		/Tamthom Truong/	Date C	Considered 04/	/09/2009					
Examiner conforman	: Initia	al if reference considered, wheth	ner or not citate of this form w	tion is in conformance with ith next communication to	n MPEP 609 applicant.	draw line thro	ough citation if not in			